COVID-19 associated coagulopathy: Thrombosis, hemorrhage and mortality rates with an escalated-dose thromboprophylaxis strategy

COVID-19 associated coagulopathy: Thrombosis, hemorrhage and mortality rates with an escalated-dose thromboprophylaxis strategy

•COVID-19 patients are at increased risk of thromboembolic complications.•Escalated-dose thromboprophylaxis may help reduce the rate of thromboembolic events.•The bleeding risk is highest for patients treated with therapeutic anticoagulation.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Thrombosis research 2020-12, Vol.196, p.483-485
Hauptverfasser: Daughety, Molly M., Morgan, Andrew, Frost, Erin, Kao, Chester, Hwang, Joyce, Tobin, Rachel, Patel, Bhavik, Fuller, Matthew, Welsby, Ian, Ortel, Thomas L.
Format: Artikel
Sprache:eng
Schlagworte:
Aged
Aged, 80 and over
Anticoagulants - administration & dosage
Anticoagulants - adverse effects
Anticoagulation
COVID
COVID-19 - complications
COVID-19 - diagnosis
COVID-19 - drug therapy
COVID-19 - mortality
Escalated-dose
Female
Hemorrhage
Hemorrhage - chemically induced
Humans
Letter to the Editors-in-Chief
Male
Middle Aged
Retrospective Studies
Risk Assessment
Risk Factors
Thromboembolism
Thromboprophylaxis
Thrombosis - diagnosis
Thrombosis - etiology
Thrombosis - mortality
Thrombosis - prevention & control
Time Factors
Treatment Outcome
Venous Thromboembolism - diagnosis
Venous Thromboembolism - etiology
Venous Thromboembolism - mortality
Venous Thromboembolism - prevention & control
VTE
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:•COVID-19 patients are at increased risk of thromboembolic complications.•Escalated-dose thromboprophylaxis may help reduce the rate of thromboembolic events.•The bleeding risk is highest for patients treated with therapeutic anticoagulation.
ISSN:0049-3848
1879-2472
DOI:10.1016/j.thromres.2020.10.004